DC-CTL targeting carbonic anhydrase IX gene combined with iAPA therapy in the treatment of renal cell carcinoma

References

• Liou LS, Shi T, Duan ZH, Sadhukhan P, Der SD, Novick AA, Hissong J, Skacel M, Almasan A, DiDonato JA, et al. Microarray gene expression profiling and analysis in renal cell carcinoma. BMC Urol. 2004;22(4):9. doi:10.1186/1471-2490-4-9.
   Google Scholar
• Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4):843–52. doi:10.1016/S0094-0143(03)00056-9.
   PubMed Web of Science ®Google Scholar
• Cohen HT, McGovern FJ. Renal-Cell Carcinoma. N Eng J Wed. 2005;353(23):2477–90. doi:10.1056/NEJMra043172.
   PubMed Web of Science ®Google Scholar
• Abel EJ, Wood CG. Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol. 2009;6(7):375–83. doi:10.1038/nrurol.2009.102.
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d’Immunothérapie. N Engl J Med 1998 30;338(18):1272–78. doi:10.1056/NEJM199804303381805.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, Hao X, Ren X. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 2012;18:1751. doi:10.1158/1078-0432.CCR-11-2442.
   PubMed Web of Science ®Google Scholar
• Evel-Kabler K, Chen SY. Inhibition of antigen-presentation attenuators to augment vaccines. Curr Opin Mol Ther. 2006;8:24–30.
   PubMedGoogle Scholar
• Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol. 2004;22(12):1546–53. doi:10.1038/nbt1035.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Wang XF, Zhang Y, Wang JY, Luan N, Surgery N. Research of SOCS1 silent DC vaccine on laryngocarcinoma therapy. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012;26:169–73.
   PubMedGoogle Scholar
• Murakami Y, Kanda K, Tsuji M, Kanayama H, Kagawa S. MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int. 1999;83(7):743–47. doi:10.1046/j.1464-410x.1999.00007.x.
   PubMed Web of Science ®Google Scholar
• Bui MHT, Seligson D, Han K, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802–11.
   PubMed Web of Science ®Google Scholar
• Duivenvoorden WC, Hopmans SN, Gallino D, Farrell T, Gerdes C, Glennie D, Lukka H, Pinthus JH. Inhibition of carbonic anhydrase IX (CA9) sensitizes renal cell carcinoma to ionizing radiation. Oncol Rep. 2015;34:1968–76. doi:10.3892/or.2015.4184.
   PubMed Web of Science ®Google Scholar
• Lucarini L, Magnelli L, Schiavone N, Crisci A, Innocenti A, Puccetti L, Cianchi F, Peri S, Supuran CT, Papucci L, et al. Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma. J Enzyme Inhib Med Chem. 2018 Dec;33(1):234–40. doi:10.1080/14756366.2017.1411350.
   PubMed Web of Science ®Google Scholar
• Zitzmann K, Brand S, De Toni EN, Baehs S, Göke B, Meinecke J, Spöttl G, Meyer HH, Auernhammer CJ. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res. 2007;67(10):5025–32. doi:10.1158/0008-5472.CAN-06-2575.
   PubMed Web of Science ®Google Scholar
• Rammah M, Dandachi F, Salman R, Shihadeh A, El-Sabban M. In vitro cytotoxicity and mutagenicity of mainstream waterpipe smoke and its functional consequences on alveolar type II derived cells. Toxicol Lett. 2012;211:220–31. doi:10.1016/j.toxlet.2012.04.003.
   PubMed Web of Science ®Google Scholar
• Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res. 1986;46:4109.
   PubMed Web of Science ®Google Scholar
• Uemura H, Fujimoto K, Tanaka M, Yoshikawa M, Hirao Y, Uejima S, Yoshikawa K, Itoh K. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 2006 15;12(6):1768–75. doi:10.1158/1078-0432.CCR-05-2253.
   PubMed Web of Science ®Google Scholar
• George DJ, Kaelin WG Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003 31;349(5):419–21. doi:10.1056/NEJMp030061.
   PubMed Web of Science ®Google Scholar
• Floreslangarica A, Müller KL, Persson EK, Cook CN, Bobat S, Marshall JL, Dahlgren MW, Hägerbrand K, Toellner KM, Goodall MD. CD103+CD11b+ mucosal classical dendritic cells initiate long-term switched antibody responses to flagellin. Mucosal Immunol. 2018;11(3):681–92. doi:10.1038/mi.2017.105.
   PubMed Web of Science ®Google Scholar
• Zhang B, Chassaing B, Shi Z, Uchiyama R, Zhang Z, Denning TL, Crawford SE, Pruijssers AJ, Iskarpatyoti JA, Estes MK. Viral infection. Prevention and cure of rotavirus infection via TLR5/NLRC4-mediated production of IL-22 and IL-18. Science. 2014;346:861–65. doi:10.1126/science.1256999.
   PubMed Web of Science ®Google Scholar
• Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, Kurnasov OV, Fort FL, Osterman AL, Didonato JA. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science. 2008;320:226–30. doi:10.1126/science.1154986.
   PubMed Web of Science ®Google Scholar
• Letran SE, Lee SJ, Shaikh A, Uematsu S, Akira S, Mcsorley SJI. TLR5 functions as an endocytic receptor to enhance flagellin-specific adaptive immunity. Eur J Immunol. 2011;41:29–38. doi:10.1002/eji.201040717.
   PubMed Web of Science ®Google Scholar
• Hong B, Ren W, Song XT, Evel-Kabler K, Chen SY and Huang XF. Human SOCS1 controls immunostimulatory activity of monocyte-derived dendritic cells. Cancer Res. 2009;69:8076. doi:10.1158/0008-5472.CAN-09-1507.
   PubMed Web of Science ®Google Scholar
• Evel-Kabler K, Song XT, Aldrich M, Huang XF, Chen SY. SOCS1 restricts dendritic cells’ ability to break self-tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest. 2005;116(1):90–100. doi:10.1172/JCI26169.
   PubMed Web of Science ®Google Scholar
• Tatsumi T1, Takehara T, Yamaguchi S, Sasakawa A, Sakamori R, Ohkawa K, Kohga K, Uemura A, Hayashi N. Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liver tumor. Hepatology. 2007 Jan;45(1):22–30. doi:10.1002/hep.21447.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 1996;183:87–97. doi:10.1084/jem.183.1.87.
   PubMed Web of Science ®Google Scholar